Skip to main content

Table 2 Clinical characteristics of non-infectious Uveitis cases treated with Rituximab

From: Rituximab for non-infectious Uveitis and Scleritis

Identified cause of Uveitis

Number (Percentage)

Age (years)

Gender (M:F)

Anatomical Localization (Ratio, %)

Time from Diagnosis to Rituximab Treatment (months)

Rituximab Regimen (Ratio, %)

Positive Therapeutic Response (Ratio, %)

Recurrence (Ratio, %)

Adverse Events (Ratio, %)

Non-paraneoplastic autoimmune retinopathy

30 (28.0%)

Mean: 50.7 ± 16.7

Median: 52.5

Range: 10.0–75.0

0.25:1

Posterior uveitis

(30/30, 100%)

Mean: 18.4

Median: 15.0

Range: 2.0–48.0

Rheumatologic

(7/30, 23.3%);

Oncologic

(3/30, 10.0%);

Foster (6/30, 20.0%);

Other (5/30, 16.7%);

Rheumatologic or oncologic

(9/30, 30.0%)

24/30, 80.0%

1/24, 4.2%

None (17/26, 65.4%);

Unspecified infusion reaction

(4/26, 15.4%);

Sinusitis (1/26, 7.7%);

Infusion reaction with tachycardia (1/26, 3.8%);

Leukopenia (1/26, 3.8%);

unspecified dermatitis (1/26, 3.8%);

Sinusitis, Herpes zoster, nodular scleritis (1/26, 3.8%)

Juvenile idiopathic arthritis

21 (19.6%)

Mean: 20.7 ± 5.7

Median: 21.0

Range: 13.0–34.0

0.12:1

Anterior uveitis (18/21, 85.7%);

Unspecified uveitis (2/21, 9.5%);

Anterior and intermediate uveitis (1/21, 4.8%);

Mean: 48.0Median: 36.0

Range: 24.0–168.0

Rheumatologic (11/21, 52.4%);

Two infusions of 375 mg/m2

separated by 2 weeks (10/21, 47.6%)

16/21, 76.2%

11/16, 68.8%

None (21/21, 100%)

Vogt-Koyanagi-Harada disease

12 (11.2%)

Mean: 23.4 ± 10.8

Median: 21.0

Range: 8.0–41.0

100% F

Anterior uveitis (8/11, 72.7%);

Panuveitis (3/11, 27.3%)

Mean: 49.5

Median: 36.0

Range: 10.0–156.0

Rheumatologic (8/12, 66.7%);

Other (4/12, 33.3%)

12/12, 100%

0/12, 0%

None (10/10, 100%)

Behcet’s disease

11 (10.3%)

Mean: 28.8 ± 10.7

Median: 28.0

Range: 17.0–51.0

1.75:1

Posterior uveitis (11/11, 100%)

NR

Rheumatologic (11/11, 100%)

11/11, 100%

10/11, 90.9%b

None (6/11, 54.5%);

Conjunctivitis (2/11, 18.2%);

Pneumonia (1/11, 9.1%);

Herpes zoster (1/11, 9.1%);

Flushing (1/11, 9.1%);

Mild urticaria (1/11, 9.1%)

Cancer-associated and Melanoma-associated retinopathy

11 (10.3%)a

Mean: 63.3 ± 13.5

Median: 61.0

Range: 46.0–86.0

0.38:1

Posterior Uveitis (11/11, 100%)

Mean: 19.1

Median: 12.5

Range: 0–75.0

Either rheumatologic or oncologic protocol (9/11, 81.8%);

Unspecified (2/11, 18.2%)

6/11, 54.5%

N/A

None

(6/8, 75%);

Infusion reaction

(2/8, 25%)

Sarcoidosis

4 (3.7%)

Mean: 47.75

Median: 47.5

Range: 46.0–50.0

100% F

Panuveitis (3/4, 75.0%)

Unspecified uveitis (1/4, 25.0%)

NR

Rheumatologic (4/4, 100%)

3/4, 75.0%

NR

Neutropenia (2/4, 50.0%);

Staphylococcus aureus skin infections (1/4, 25.0%);

None (1/4, 25.0%)

Otherc

9 (8.4%)

Mean: 48.0 ± 9.6

Median: 42.0

Range: 37.0–62.0

0.5:1

Posterior uveitis (3/9, 33.3%);

Panuveitis (2/9, 22.2%);

Anterior uveitis (1/9, 11.1%);

Anterior and intermediate uveitis (1/9, 11.1%);

Anterior uveitis and vasculitis (1/9, 11.1%);

Unspecified uveitis and vasculitis (1/9, 11.1%)

NR

Rheumatologic (3/8, 37.5%);

Foster (4/8, 50.0%);

Other (1/8, 12.5%)

5/5, 100%

1/5, 20.0%

None (3/3, 100%)

Indeterminate

9 (8.4%)

Mean: 43.2 ± 19.0

Median: 49.0

Range: 14.0–65.0

0.13:1

Panuveitis (5/9, 55.6%);

Posterior uveitis (2/9, 22.2%);

Anterior uveitis

(2/9, 22.2%)

NR

Foster(7/9, 77.8%);

Rheumatologic (1/9, 11.1%);

Oncologic (1/9, 11.1%)

4/4, 100%

1/4, 25%

None (1/3, 33.3%);

Fungal skin infection (1/3, 33.3%);

Gastrointestinal discomfort (1/3, 33.3%)

  1. M male, F female, NR not reported, Rheumatologic = Two doses of 1000 mg separated by 14 days, Oncologic = four doses of 375 mg/m2 weekly, Foster = eight doses of 375 mg/m2 weekly, Other = all other RTX dosing regimens
  2. a = 10 cases of cancer-assocaited retinopathy, and one case of melanoma-associated retinopathy
  3. b = all patients only received one cycle of rituximab, recurrences occurred between 6 and 13 months, with a median of 7.5 months, after treatment
  4. c = includes 3 cases of GPA, 2 cases of SLE, and 1 case each of HLA-B27, multiple sclerosis, type 2 essential cryoglobulinemia, and birdshot chorioretinitis